Literature DB >> 31839858

tPA for Acute Ischemic Stroke and Its Controversies: A Review.

Brian Dewar1, Michel Shamy1.   

Abstract

BACKGROUND AND
PURPOSE: Although neurologists consider intravenous tissue plasminogen activator (tPA) to be standard of care in the treatment of patients with acute ischemic stroke, its use remains contentious within the broader medical community, and particularly among emergency physicians. Why might this be? We provide a historical context to this ongoing controversy by reviewing how neurologists have conceptualized the acute stroke and its treatment, with the aim of bridging this gap.
METHODS: Based on historical sources in the Mackie Family History of Neuroscience Collection at the University of Calgary, as well as online resources, we trace the evolution of the concept of the "acute stroke," which has come to mean a stroke that is potentially treatable with tPA. We frame this conceptualization in relation to historical "building blocks" in anatomy, pathology, and physiology. We then use these building blocks to explain why neurologists understand tPA to be effective and why emergency physicians often do not. RESULTS AND
CONCLUSIONS: Arguments against the use of tPA reiterate 20-year-old concerns about its efficacy and safety. We believe these persistent concerns can be framed as a lack of understanding of the "building blocks" upon which neurologists' conception of tPA is built. Our view suggests that the way forward to bridge the gap between neurology and other disciplines is not to conduct more trials but to offer a shared conceptualization of the trials already completed and of the intellectual tradition from which they emerged.
© The Author(s) 2019.

Entities:  

Keywords:  cerebrovascular disorders; education; epidemiology; outcomes; stroke; techniques

Year:  2019        PMID: 31839858      PMCID: PMC6900654          DOI: 10.1177/1941874419838961

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  23 in total

Review 1.  Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.

Authors:  Jeanne Lenzer
Journal:  BMJ       Date:  2002-03-23

2.  A pathology of the animal spirits -- the clinical neurology of Thomas Willis (1621-1675) part I -- background, and disorders of intrinsically normal animal spirits.

Authors:  M J Eadie
Journal:  J Clin Neurosci       Date:  2003-01       Impact factor: 1.961

3.  Emergency physician survey: recombinant tissue plasminogen activator for stroke.

Authors:  Jeffrey Mann
Journal:  Ann Emerg Med       Date:  2006-10       Impact factor: 5.721

4.  Morgagni on apoplexy in De Sedibus: a historical perspective.

Authors:  Henry S Schutta
Journal:  J Hist Neurosci       Date:  2009       Impact factor: 0.529

5.  The latest national clinical guideline for stroke.

Authors:  Anthony George Rudd; Audrey Bowen; Gavin R Young; Martin A James
Journal:  Clin Med (Lond)       Date:  2017-04       Impact factor: 2.659

6.  Tissue plasminogen activator for acute ischemic stroke: a New York city emergency medicine perspective.

Authors:  Yu-Feng Chan; Thomas G Kwiatkowski; Joseph G Rella; William P Rennie; Robert K Kwon; Robert A Silverman
Journal:  J Emerg Med       Date:  2005-11       Impact factor: 1.484

7.  Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals.

Authors:  Phillip A Scott; Zhenzhen Xu; William J Meurer; Shirley M Frederiksen; Mary N Haan; Michael W Westfall; Sandip U Kothari; Lewis B Morgenstern; John D Kalbfleisch
Journal:  Stroke       Date:  2010-08-12       Impact factor: 7.914

Review 8.  Intravenous Recombinant Tissue Plasminogen Activator and Ischemic Stroke: Focused Update of 2010 Clinical Practice Advisory From the American Academy of Emergency Medicine.

Authors:  William J Meurer; Bradley Barth; Michael Abraham; Jerome R Hoffman; Gary M Vilke; Gerard DeMers
Journal:  J Emerg Med       Date:  2018-03-12       Impact factor: 1.484

9.  A graphic reanalysis of the NINDS Trial.

Authors:  Jerome R Hoffman; David L Schriger
Journal:  Ann Emerg Med       Date:  2009-05-23       Impact factor: 5.721

10.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  4 in total

1.  Salidroside Inhibits Reactive Astrogliosis and Glial Scar Formation in Late Cerebral Ischemia via the Akt/GSK-3β Pathway.

Authors:  Chengya Dong; Shaohong Wen; Shunying Zhao; Si Sun; Shangfeng Zhao; Wen Dong; Pingxin Han; Qingfang Chen; Ting Gong; Wentao Chen; Wenqian Liu; Xiangrong Liu
Journal:  Neurochem Res       Date:  2021-01-03       Impact factor: 3.996

2.  Potential accuracy of prehospital NIHSS-based triage for selection of candidates for acute endovascular stroke therapy.

Authors:  Jeffrey G Klingman; Janet G Alexander; David R Vinson; Lauren E Klingman; Mai N Nguyen-Huynh
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-05-01

3.  Thrombolytic Therapy During ex-vivo Normothermic Machine Perfusion of Human Livers Reduces Peribiliary Vascular Plexus Injury.

Authors:  Omar Haque; Siavash Raigani; Ivy Rosales; Cailah Carroll; Taylor M Coe; Sofia Baptista; Heidi Yeh; Korkut Uygun; Francis L Delmonico; James F Markmann
Journal:  Front Surg       Date:  2021-06-17

4.  Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape.

Authors:  Latha Ganti; Bryan Kwon; Andrew George; Thor Stead; Cherian Plamoottil; Paul Banerjee
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-01-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.